Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 89/100

Targeted fat-burning peptide fragment that accelerates fat release from adipocytes without affecting blood sugar or insulin levels.

Knowledge Graph:Vector: Bone MatrixProteostasis
Head-to-Head CompareAudit in Stack
peptideBone MatrixSilver Tier85–943rdin Peptides of 14Moderate Confidence (Translational)⚖️ Scientific Consensus: Stable

AOD-9604 SubQ (300–500 mcg Daily Fasted)

Targeted fat-burning peptide fragment that accelerates fat release from adipocytes without affecting blood sugar or insulin levels.

89/100
High Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

Targeted fat-burning peptide fragment that accelerates fat release from adipocytes without affecting blood sugar or insulin levels.

2. Major Unanswered Scientific Uncertainty

Long-term multi-cohort replication and optimal individualization remain active areas of study.

Strongest Supporting TrialPMID:16822820

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults

DOUBLE BLIND RCT • Sample: N = 64

“Mean 24-Hour Growth Hormone and IGF-1 Concentrations: +150%”

Strongest Counter-Evidence / RiskPMID:view

Safety Boundary & Dosing Considerations

Clinical Safety Assessment

“Individual variation in bioavailability and optimal dosing thresholds.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Large prospective dose-ranging RCT over 12 months.
Expected Impact: Identify minimum therapeutic threshold and safety limits.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Neutral Pathway
0/ 100

No direct primary biochemical modulation of heart health; pathway is neutral for Growth Hormone Secretagogue Peptides (CJC-1295 / Ipamorelin / AOD-9604).

Brain Longevity & Cognition

Neutral Pathway
0/ 100

No direct primary biochemical modulation of brain longevity; pathway is neutral for Growth Hormone Secretagogue Peptides (CJC-1295 / Ipamorelin / AOD-9604).

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

No direct primary biochemical modulation of metabolic health; pathway is neutral for Growth Hormone Secretagogue Peptides (CJC-1295 / Ipamorelin / AOD-9604).

Cancer Defense & Autophagy

Foundational Target (65-100)
84/ 100

Restores youthful physiological GH pulse amplitude, stimulating hepatic IGF-1 synthesis and enhancing thymic T-cell lymphopoiesis (the basis of the TRIIM epigenetic trial).

Serum ThymulinExtracellular Matrix TurnoverDeep Slow-Wave Sleep Duration
Reversal of epigenetic aging and immunosenescent trends in humans (TRIIM Trial)PMID: 31496122

Endocrine Vitality & Anabolic Tone

Foundational Target (65-100)
76/ 100

CJC-1295 (GHRH analogue) binds the GHRH receptor on somatotrophs while Ipamorelin selectively activates the ghrelin receptor (GHS-R1a), synergistically stimulating clean, pulsatile pituitary growth hormone release without raising cortisol or prolactin.

Serum IGF-1Nocturnal GH Area Under CurveLean Muscle Mass
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295PMID: 16822820

Systemic Inflammation Suppression

Foundational Target (65-100)
84/ 100

Restores youthful physiological GH pulse amplitude, stimulating hepatic IGF-1 synthesis and enhancing thymic T-cell lymphopoiesis (the basis of the TRIIM epigenetic trial).

Serum ThymulinExtracellular Matrix TurnoverDeep Slow-Wave Sleep Duration
Reversal of epigenetic aging and immunosenescent trends in humans (TRIIM Trial)PMID: 31496122

Bone Density & Connective Matrix

Foundational Target (65-100)
89/ 100

CJC-1295 (GHRH analogue) binds the GHRH receptor on somatotrophs while Ipamorelin selectively activates the ghrelin receptor (GHS-R1a), synergistically stimulating clean, pulsatile pituitary growth hormone release without raising cortisol or prolactin.

Serum IGF-1Nocturnal GH Area Under CurveLean Muscle Mass
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295PMID: 16822820

Cellular Longevity & Epigenetics

Foundational Target (65-100)
84/ 100

Restores youthful physiological GH pulse amplitude, stimulating hepatic IGF-1 synthesis and enhancing thymic T-cell lymphopoiesis (the basis of the TRIIM epigenetic trial).

Serum ThymulinExtracellular Matrix TurnoverDeep Slow-Wave Sleep Duration
Reversal of epigenetic aging and immunosenescent trends in humans (TRIIM Trial)PMID: 31496122
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Youthful Pituitary GH Pulsatility & Lean Tissue Regeneration
Secondary Clinical Endpoints:
Deep Sleep Slow-Wave Amplitude AmplificationVisceral Lipolysis StimulationSkin Matrix Collagen Density
LEVL Recommended Tracking Metrics:
recoverymuscle massSleep Quality

Regenerative Recovery

92/99
Very High EffectGrade B (Endocrine Society Human Clinical Trials)8-12 weeks cycle
CJC-1295 Pharmacokinetics and IGF-1 Elevation in Healthy AdultsPMID: 16822820

Clinical Endpoint: Pulsed nightly administration preserves natural feedback loops and avoids pituitary desensitization while elevating serum IGF-1 into optimal youthful ranges.

regenerative_recovery

Physical Energy

daily wellbeing
85/99
High EffectGrade B (Human Clinical Cohort)2-6 weeks
The effects of human growth hormone lipolytic fragment (AOD9604) on lipid metabolism and beta-3 adrenergic receptorsPMID: 11701633

Clinical Endpoint: Endocrinology study proving AOD9604 stimulates lipolysis and inhibits lipogenesis without altering IGF-1 levels or inducing insulin resistance.

physical_energy

Joint Comfort

daily wellbeing
78/99
High EffectGrade B (Clinical Evidence)3-8 weeks
AOD9604 intra-articular and systemic cartilage regenerative efficacy in osteoarthritis modelsPMID: 26273469

Clinical Endpoint: Stimulates proteoglycan synthesis in articular cartilage and promotes joint recovery.

joint_comfort
Explainable Longevity Score Decomposition

Score Breakdown: 89 / 100

Confidence Interval:±6.5%
Synergy Multiplier:1x
Evidence Strength82/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude98/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index84/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit90/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility96/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Synthesized from 1 verified trials (N=64 pooled participants) across 82/100 evidence strength and 98/100 effect magnitude.

Practicality, Cost & Adherence Index

Monthly Cost
$0 (Free / Behavioral)
Time Commitment
15 min/day
~1.5 hrs/week
Adherence Friction
3/10
Moderate Discipline Required
Accessibility
over the counter
Granular Clinical Study Ledger

AOD-9604 SubQ (300–500 mcg Daily Fasted) Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
1
Human RCTs
1
Pooled N
64
Avg RoB
1.3 / 5
Human Clinical (n=64)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.3

Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults

Teichman SL, et al.•Journal of Clinical Endocrinology & Metabolism•2006•N = 64•4 wks
Intervention Protocol: Standard clinical protocol parameters
Cohort: Clinical study population
Quantitative Endpoints & Effect Sizes
Mean 24-Hour Growth Hormone and IGF-1 Concentrations+150%
+150%p < 0.05
Clinical Takeaway:Demonstrated safe 2- to 3-fold increases in mean GH concentration and 1.5-fold increases in circulating IGF-1 while preserving physiologic pulsatility.
Independent Academic Research
PubMed: 16822820DOI
Chronological Evolution of Evidence

AOD-9604 SubQ (300–500 mcg Daily Fasted) Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

AOD-9604 SubQ (300–500 mcg Daily Fasted) Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

No absolute contraindications reported for healthy adults.

Pharmacological & Supplement Interactions

No high-risk pharmacokinetic interactions documented.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • Transient and mild when used at therapeutic doses.

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Premenopausal women
  • Pediatric cohorts
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)